See more : NewSoft Technology Corporation (5202.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of VistaGen Therapeutics, Inc. (VTGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VistaGen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sure Ventures Plc (SURE.L) Income Statement Analysis – Financial Results
- Decibel Cannabis Company Inc. (DB.V) Income Statement Analysis – Financial Results
- PT Aneka Gas Industri Tbk (AGII.JK) Income Statement Analysis – Financial Results
- Gjensidige Forsikring ASA (GJNSY) Income Statement Analysis – Financial Results
- Shanghai Action Education Technology CO.,LTD. (605098.SS) Income Statement Analysis – Financial Results
VistaGen Therapeutics, Inc. (VTGN)
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 103.10K | 91.20K | 80.70K | 0.00 | 53.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 20.02M | 44.38M | 35.41M | 11.93M | 13.37M | 17.10M | 7.76M | 5.20M | 3.93M | 2.43M | 2.48M | 3.43M | 5.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.06M | 14.66M | 10.45M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.39K | 21.54K | 16.35K | 4.78K |
| Selling & Marketing | 0.00 | 1.90M | 2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.06M | 14.66M | 13.25M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.52K | 21.54K | 16.35K | 4.78K |
| Other Expenses | 0.00 | 0.00 | 232.00K | -400.00 | -827.00K | -48.70K | -428.00K | 426.80K | -2.30K | -233.00K | 0.00 | 0.00 | 641.00K | 428.00 | 428.00 | 36.00 | 0.00 |
| Operating Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Cost & Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Interest Income | 0.00 | 49.00K | 20.00K | 15.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 10.00K | 30.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 23.00K | 0.00 | 13.00K | 15.00K | 8.00K | 8.90K | 5.00K | 777.00K | 4.62M | 1.56M | 1.00M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 568.00K | 532.00K | 711.10K | 477.60K | 103.10K | 91.20K | 80.70K | 54.90K | 53.50K | 59.10K | 54.60K | 33.80K | 45.60K | 428.00 | 428.00 | 36.00 | 0.00 |
| EBITDA | -32.45M | -58.74M | -47.05M | -17.44M | -20.65M | -24.47M | -14.25M | -9.77M | -17.80M | -6.72M | -4.97M | -11.85M | -10.27M | -6.32M | -21.54K | -16.35K | -4.78K |
| EBITDA Ratio | -3,050.09% | 25,816.45% | -4,221.83% | -1,633.87% | 0.00% | 0.00% | 0.00% | -815.46% | 0.00% | 0.00% | 0.00% | -3,340.62% | -670.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.02M | -59.27M | -47.78M | -17.93M | -20.80M | -24.56M | -14.20M | -10.25M | -17.85M | -6.78M | -5.03M | -6.79M | -9.04M | -8.95K | -21.97K | -16.39K | -4.78K |
| Operating Income Ratio | -3,103.48% | 26,040.74% | -4,308.68% | -1,646.06% | 0.00% | 0.00% | 0.00% | -819.88% | 0.00% | 0.00% | 0.00% | -3,389.77% | -673.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.66M | 26.00K | 19.90K | 2.20K | 30.10K | -30.70K | -143.90K | -4.60K | -29.37M | -7.11M | 2.06M | -6.09M | -3.16M | -9.47M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -29.36M | -59.24M | -47.76M | -17.93M | -20.77M | -24.59M | -14.34M | -10.25M | -47.22M | -13.88M | -2.97M | -12.88M | -12.21M | -8.95K | -21.97K | -16.39K | -4.78K |
| Income Before Tax Ratio | -2,759.21% | 26,063.26% | -4,306.88% | -1,645.86% | 0.00% | 0.00% | 0.00% | -820.25% | 0.00% | 0.00% | 0.00% | -6,428.64% | -909.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00K | 6.00K | 3.40K | 2.60K | 2.60K | 2.60K | 2.40K | 2.40K | 2.30K | 2.40K | 2.70K | 3.70K | 1.60K | 30.00 | 30.00 | 30.00 | -30.00 |
| Net Income | -29.36M | -59.25M | -47.76M | -17.93M | -20.77M | -24.59M | -14.35M | -10.26M | -47.22M | -13.89M | -2.97M | -12.89M | -12.21M | -8.98K | -22.00K | -16.42K | -4.75K |
| Net Income Ratio | -2,759.59% | 26,065.86% | -4,307.19% | -1,646.09% | 0.00% | 0.00% | 0.00% | -820.44% | 0.00% | 0.00% | 0.00% | -6,430.49% | -909.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.28 | -318.27 | -74.47 | -426.99 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| EPS Diluted | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.27 | -315.87 | -81.00 | -426.98 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| Weighted Avg Shares Out | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.63K | 39.85K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
| Weighted Avg Shares Out (Dil) | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.96K | 36.64K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
PRISM MarketView – Weekly Market Report – April 26, 2024
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
Source: https://incomestatements.info
Category: Stock Reports